Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens

Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in individual patients is challenging. Previous methods have restricted antigen discovery to selected HLA alleles, thereby limiting the breadth of ne...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature biotechnology Ročník 41; číslo 6; s. 783 - 787
Hlavní autori:	Cattaneo, Chiara M., Battaglia, Thomas, Urbanus, Jos, Moravec, Ziva, Voogd, Rhianne, de Groot, Rosa, Hartemink, Koen J., Haanen, John B. A. G., Voest, Emile E., Schumacher, Ton N., Scheper, Wouter
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	New York Nature Publishing Group US 01.06.2023 Nature Publishing Group
Predmet:	631/250/251 631/61/191 631/67/580 Agriculture Antigens Antigens, Neoplasm Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Brief Communication Cancer CD4 antigen CD4-Positive T-Lymphocytes CD8 antigen CD8-Positive T-Lymphocytes Communication Genetic screening Genotypes Histocompatibility antigen HLA Humans Identification Life Sciences Lymphocytes Lymphocytes T Mutation Neoantigens Neoplasms Oncology Patients T cell receptors Tumors
ISSN:	1087-0156, 1546-1696, 1546-1696
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in individual patients is challenging. Previous methods have restricted antigen discovery to selected HLA alleles, thereby limiting the breadth of neoantigen repertoires that can be uncovered. Here, we develop a genetic neoantigen screening system that allows sensitive identification of CD4 + and CD8 + T cell-recognized neoantigens across patients’ complete HLA genotypes. Patient-specific tumor neoantigens are recognized by T cells.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1087-0156 1546-1696 1546-1696
DOI:	10.1038/s41587-022-01547-0